Bruce R. Rosengard

Vice President-New Business Ventures at The Medicines Co.

Bruce R. Rosengard

Bruce R. Rosengard

Vice President-New Business Ventures at The Medicines Co.

Biography

Bruce R. Rosengard is Vice President-New Business Ventures at The Medicines Co. Dr. Rosengard received an undergraduate degree from Tufts University and a doctorate from The Johns Hopkins University.

Overview
RelSci Relationships

136

Relationships
RelSci Relationships are individuals Bruce R. Rosengard likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chief Executive Officer at Rempex Pharmaceuticals, Inc.

Relationship likelihood: Average

Head, Global Communications at The Medicines Co.

Relationship likelihood: Average

Global Launch Leader, Anti-Platelet Solutions at The Medicines Co.

Relationship likelihood: Average

Head, Global Contracting & Business Ethics at The Medicines Co.

Relationship likelihood: Average

Executive Vice President, General Counsel & Secretary at The Medicines Co.

Relationship likelihood: Average

Chief Financial Officer & Treasurer at The Medicines Co.

Relationship likelihood: Average

Executive Vice President at The Medicines Co.

Relationship likelihood: Average

President, Chief Executive Officer & Director at Qpex Biopharma, Inc.

Relationship likelihood: Average

Former Head-Infectious Disease Biology at The Medicines Co.

Relationship likelihood: Average

Executive Vice President at The Medicines Co.

Relationship likelihood: Average

Paths to Bruce R. Rosengard
Potential Connections via
Relationship Science
You
Bruce R. Rosengard
Vice President-New Business Ventures at The Medicines Co.
Career History
Vice President-New Business Ventures
2012 - Current

The Medicines Co We are a global pharmaceutical company focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. In the United States, we have three marketed products, Angiomax® (bivalirudin) for Injection, Cleviprex® (clevidipine) Injectable Emulsion, and Argatroban Injection, 50 mg per 50 mL†. We also have a pipeline of acute and intensive care hospital products in development, including three late-stage development product candidates, cangrelor, oritavancin and MDCO-157, and two early stage development product candidates, MDCO-2010 and MDCO-216. We believe that Angiomax, Cleviprex and our products in development possess favorable attributes that can satisfy unmet medical needs in the acute | intensive care hospital product market and offer, or, in the case of our products in development, have the potential to offer, improved performance to hospital businesses. The Company is publicly traded on the Nasdaq exchange under the ticker symbol MDCO. It was founded in 1996 and employs approximately 425 professionals.

Other Affiliations

Bruce R. Rosengard is affiliated with The Medicines Co.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Bruce R. Rosengard. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Bruce R. Rosengard's profile does not indicate a business or promotional relationship of any kind between RelSci and Bruce R. Rosengard.